Evidence map›Paper›PMID 30381445›Full record

ArticleMolecular cancer therapeutics2019

Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target.

Darryl T Martin, Hongliang Shen, Jill M Steinbach-Rankins, Xi Zhu, Katelyn K Johnson, Jamil Syed, W Mark Saltzman, Robert M Weiss

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. [Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Darryl T MartinDepartment of Urology, Yale University, New Haven, Connecticut. darryl.martin@yale.edu.
Hongliang ShenDepartment of Urology, Yale University, New Haven, Connecticut.
Jill M Steinbach-RankinsDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut.
Xi ZhuDepartment of Urology, Yale University, New Haven, Connecticut.
Katelyn K JohnsonDepartment of Urology, Yale University, New Haven, Connecticut.
Jamil SyedDepartment of Urology, Yale University, New Haven, Connecticut.
W Mark SaltzmanDepartment of Biomedical Engineering, Yale University, New Haven, Connecticut.
Robert M WeissDepartment of Urology, Yale University, New Haven, Connecticut.
Yale University · US

Funding

Molecular and Cellular Transport in MucusR01EB000487 · NIBIB · YALE UNIVERSITY · PI IWASAKI, AKIKO, SALTZMAN, W. MARK · 2002 to 2019
$5.0M
Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseasesRC1DK087015 · NIDDK · YALE UNIVERSITY · PI WEISS, ROBERT M · 2009 to 2010
$985k
Molecular and Cellular Transport in MucusR56EB000487 · NIBIB · YALE UNIVERSITY · PI SALTZMAN, W. MARK · 2008 to 2008
$402k
NIBIB NIH HHS R01 EB000487NIBIB NIH HHS R56 EB000487NIDDK NIH HHS RC1 DK087015
6 · The paper itself

Abstract

Predicting bladder cancer progression is important in selecting the optimal treatment for bladder cancer. Because current diagnostic factors regarding progression are lacking, new factors are needed to further stratify the curative potential of bladder cancer. Glycoprotein-130 (GP130), a transmembrane protein, is central to a number of signal transduction pathways involved in tumor aggressiveness, making it an attractive target. We hypothesize that if GP130 is found in an aggressive population of bladder tumors, then blocking GP130 expression may inhibit bladder cancer growth. Herein, we quantitatively show, using 11 patient samples and four bladder cancer cell lines, that GP130 is expressed in the aggressive human bladder tumors and in high-grade bladder cancer cell lines. Moreover, GP130 is significantly correlated with tumor grade, node category, tumor category, and patient outcome. We demonstrated a tumor-specific GP130 effect by blocking GP130 expression in bladder tumor cells, which resulted in decreased cell viability and reduced cell migration. Furthermore, we reduced tumor volume by approximately 70% compared with controls by downregulating GP130 expression using chitosan-functionalized nanoparticles encapsulating GP130 siRNA in an

Indexed as

Up-RegulationAnimalsCell Line, TumorCell MovementCell ProliferationCell SurvivalCytokine Receptor gp130FemaleGene Expression Regulation, NeoplasticHumansMaleMiceNanoparticlesNeoplasm GradingNeoplasm TransplantationRNA, Small InterferingCytokine Receptor gp130IL6ST protein, humanRNA, Small Interfering

Identifiers

PMID30381445
PMCPMC6363894
OpenAlexW2898721461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.